187
IRUS TotalDownloads
Altmetric
Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin
File | Description | Size | Format | |
---|---|---|---|---|
s12916-017-0999-x.pdf | Published version | 5.79 MB | Adobe PDF | View/Open |
Title: | Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin |
Authors: | MacIntyre, DA Brown, R Marchesi, J Lee, Y Smith, A Lehne, B Kindinger, L Terzidou, V Holmes, E Nicholson, J Bennett, P |
Item Type: | Journal Article |
Abstract: | Background: Preterm prelabour rupture of the fetal membranes (PPROM) precedes 30% of preterm births and is a risk factor for early onset neonatal sepsis. As PPROM is strongly associated with ascending vaginal infection prophylactic antibiotics are widely used. The evolution of vaginal microbiota composition associated with PPROM and the impact of antibiotics on bacterial composition is unknown. Methods: We prospectively assessed vaginal microbiota prior to and following PPROM using MiSeq-based sequencing of 16S rRNA gene amplicons and examined the impact of erythromycin prophylaxis on bacterial load and community structures. Results: In contrast to pregnancies delivering at term, vaginal dysbiosis characterised by Lactobacillus spp. depletion, was present prior to the rupture of fetal membranes in approximately a third of cases (0% versus 27%, P= 0.026) and persisted following membrane rupture (31%, P= 0.005). Vaginal dysbiosis was exacerbated by erythromycin treatment (47%, P= 0.00009) particularly in women initially colonised by Lactobacillus species. Lactobacillus depletion and increased relative abundance of Sneathia spp. was associated with subsequent funisitis and early onset neonatal sepsis. Conclusions: Our data show that vaginal microbiota composition is a risk-factor for subsequent PPROM and is associated with adverse short-term maternal and neonatal outcomes. This highlights vaginal microbiota as a potentially modifiable antenatal risk factor for PPROM and suggests that routine use of erythromycin for PPROM be re-examined. |
Issue Date: | 24-Jan-2018 |
Date of Acceptance: | 20-Dec-2017 |
URI: | http://hdl.handle.net/10044/1/55525 |
DOI: | 10.1186/s12916-017-0999-x |
ISSN: | 1741-7015 |
Publisher: | BioMed Central |
Journal / Book Title: | BMC Medicine |
Volume: | 16 |
Copyright Statement: | © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
Sponsor/Funder: | Medical Research Council (MRC) Medical Research Council (MRC) Imperial College Healthcare NHS Trust- BRC Funding Biotechnology and Biological Sciences Research Council (BBSRC) Medical Research Council (MRC) Imperial College Healthcare NHS Trust- BRC Funding Kristian Gerhard Jebsen Foundation Bowel & Cancer Research National Institute for Health Research Imperial College Healthcare NHS Trust- BRC Funding Imperial College Healthcare NHS Trust- BRC Funding Seattle ChildrensHospital Research Foundation The Academy of Medical Sciences Imperial College Healthcare NHS Trust- BRC Funding Imperial College Healthcare NHS Trust- BRC Funding Imperial College Healthcare NHS Trust- BRC Funding Imperial College Healthcare NHS Trust- BRC Funding Imperial College Healthcare NHS Trust- BRC Funding Imperial Health Charity Medical Research Council Medical Research Council (MRC) Imperial College London St Stephen's Aids Trust National Institute for Health Research |
Funder's Grant Number: | MR/L009226/1 MR/L009226/1 RDD03 79560 BB/L020858/1 BH124127 RDA01 79560 None Given N/A EME/13/121/07 RDA05 79560 RDB04 N/A Springboard RDA27 RDA27 RDA27 RDA27 RDA02 RF17/1011 MR/R00875/1 MR/R000875/1 SSAT054 EME/13/121/07 |
Keywords: | Science & Technology Life Sciences & Biomedicine Medicine, General & Internal General & Internal Medicine Vaginal microbiota Preterm birth Preterm prelabour rupture of membranes Antibiotics Erythromycin Neonatal sepsis Pregnancy PREMATURE RUPTURE BACTERIAL-VAGINOSIS ANTIMICROBIAL SUSCEPTIBILITY INTRAAMNIOTIC INFLAMMATION CHILDHOOD OUTCOMES ANTIBIOTIC-THERAPY PRELABOR RUPTURE MICROBIOTA BIRTH CHORIOAMNIONITIS Antibiotics Erythromycin Neonatal sepsis Pregnancy Preterm birth Preterm prelabour rupture of membranes Vaginal microbiota Adult Antibiotic Prophylaxis Cohort Studies Disease Progression Dysbiosis Erythromycin Female Fetal Membranes, Premature Rupture Humans Infant, Newborn Microbiota Neonatal Sepsis Pregnancy Premature Birth Prenatal Care RNA, Bacterial RNA, Ribosomal, 16S Risk Factors Vagina Vagina Humans Fetal Membranes, Premature Rupture Premature Birth Disease Progression Erythromycin RNA, Bacterial RNA, Ribosomal, 16S Antibiotic Prophylaxis Prenatal Care Risk Factors Cohort Studies Pregnancy Adult Infant, Newborn Female Microbiota Dysbiosis Neonatal Sepsis 11 Medical and Health Sciences General & Internal Medicine |
Publication Status: | Published |
Article Number: | 9 |
Online Publication Date: | 2018-01-24 |
Appears in Collections: | Department of Metabolism, Digestion and Reproduction Faculty of Medicine School of Public Health |